Lenvatinib has been evaluated across numerous clinical trials targeting diverse oncological conditions, including hepatocellular carcinoma, endometrial adenocarcinoma, Kaposi sarcoma, and central nervous system tumors. Spanning from early Phase 1 to late Phase 4 studies, these monotherapy and combination regimens are sponsored by academic medical centers, public health institutions, and industry collaborators. Across these investigations, recruitment statuses vary widely, encompassing active recruiting, completed, active not recruiting, terminated, and withdrawn trials.
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT03486873 | RECRUITING | Solid Tumors; Hematologic Malignancies |
Merck Sharp & Dohme LLC |
2018-08-21 | PHASE3 |
| NCT07383441 | RECRUITING | Advanced Clear Cell Renal Cell Carcinoma; Metastatic Clear Cell Renal Cell Carcinoma; Stage III Renal Cell Cancer AJCC v8; Stage IV Renal Cell Cancer AJCC v8 |
SWOG Cancer Research Network |
2026-06-05 | PHASE3 |
| NCT07432568 | NOT_YET_RECRUITING | Intrahepatic Cholangiocarcinoma |
Tianjin Medical University Cancer Institute and Hospital |
2026-03-09 | PHASE2 |
| NCT06364631 | RECRUITING | Metastatic Kidney Cancer; Metastatic Kidney Carcinoma |
Gustave Roussy, Cancer Campus, Grand Paris |
2024-04-12 | PHASE3 |
| NCT07290894 | RECRUITING | Vulva Cancer |
National Cancer Institute, Naples |
2026-03-12 | PHASE2 |
| NCT07594015 | RECRUITING | Recurrent Endometrial Cancer |
University of Miami |
2026-08-06 | PHASE2 |
| NCT07460206 | NOT_YET_RECRUITING | ccRCC |
Gruppo Oncologico Italiano di Ricerca Clinica |
2026-08 | PHASE2 |
| NCT07537946 | NOT_YET_RECRUITING | Hepatocellular Carcinoma (HCC); Metastases |
Tongji Hospital |
2026-05-30 | PHASE3 |
| NCT06726421 | RECRUITING | Renal Cell Carcinoma (Kidney Cancer); Kidney Cancer Metastatic; Renal Cell Carcinoma Metastatic |
Sun Yat-sen University |
2024-09-18 | PHASE3 |
| NCT06858813 | RECRUITING | Hepatocellular Cancer; Squamous-Cell Non-Small Cell Lung Cancer |
AbbVie |
2025-04-14 | PHASE1 |
| NCT07738159 | NOT_YET_RECRUITING | Extrapulmonary Neuroendocrine Carcinoma (EP-NEC); QL1706; Lenvatinib; Chemotherapy |
West China Hospital |
2026-08-01 | PHASE2 |
| NCT07550972 | ENROLLING_BY_INVITATION | Squamous Cell Carcinoma of the Head and Neck |
Zhejiang Provincial People's Hospital |
2026-05-01 | PHASE2 |
| NCT07691515 | NOT_YET_RECRUITING | Intrahepatic Cholangiocarcinoma (Icc) |
Zhejiang Cancer Hospital |
2026-07 | PHASE3 |
| NCT06030037 | WITHDRAWN | PD-1 Refractory Advanced Melanoma |
Diwakar Davar |
2025-03-11 | PHASE2 |
| NCT07715565 | NOT_YET_RECRUITING | Renal Cell Carcinoma (Kidney Cancer); Immunotherapy; Molecular Targeted Therapy |
West China Hospital |
2026-08 | PHASE2 |
| NCT07277972 | NOT_YET_RECRUITING | RCC, Renal Cell Cancer |
Tianjin Medical University Cancer Institute and Hospital |
2026-02-15 | PHASE2 |
| NCT07683949 | ENROLLING_BY_INVITATION | Advanced Colorectal Cancer (Part 1) |
Seoul National University Bundang Hospital |
2026-06-15 | PHASE1; PHASE2 |
| NCT07368985 | NOT_YET_RECRUITING | Cervical Cancer by FIGO Stage 2018; Squamous Cell Carcinoma FIGO 2018 Stage IIIA, IIIB, IIIC1-IIIC2; Adenocarcinoma or Adeno-squamous Carcinoma Stage IB3-IIIC2 |
Prof. Dr. Remi A. Nout |
2026-03 | PHASE2 |
| NCT07501104 | NOT_YET_RECRUITING | Melanoma (Skin Cancer) |
Shanghai Zhongshan Hospital |
2026-05-01 | PHASE2 |
| NCT07219459 | RECRUITING | Unresectable or Metastatic Hepatocellular Carcinoma; Child-Pugh A Hepatocellular Carcinoma; Failure of First-Line Treatment That Included an Approved Anti PD-(L)1 Compound |
CatalYm GmbH |
2026-03-19 | PHASE2 |
| NCT07754734 | NOT_YET_RECRUITING | Glioma; Glioblastoma (GBM); MGMT-Methylated Glioblastoma |
Dongguan People's Hospital |
2026-08-10 | PHASE2 |
| NCT06580574 | RECRUITING | Gastric Cancer; Colon Cancer; MSI-H; DMMR Cancer |
Peking University |
2024-09-13 | PHASE2 |
| NCT06904183 | RECRUITING | Hepatocellular Carcinoma Non-resectable |
Second Affiliated Hospital of Guangzhou Medical University |
2025-04-01 | PHASE2 |
| NCT06669572 | RECRUITING | Carcinoma, Squamous Cell; Anorectal Cancer |
University of Chicago |
2025-07-11 | PHASE2 |
| NCT07636798 | RECRUITING | Biliary Tract Cancer |
West China Hospital |
2026-06 | PHASE1; PHASE2 |
| NCT07099794 | NOT_YET_RECRUITING | Biliary Tract Cancer (BTC) |
Cancer Institute and Hospital, Chinese Academy of Medical Sciences |
2025-08-01 | PHASE2 |
| NCT07384416 | RECRUITING | Penile Cancer |
Sun Yat-sen University |
2026-04-10 | PHASE2 |
| NCT07328009 | RECRUITING | Hepato Cellular Carcinoma (HCC) |
Fudan University |
2026-01-19 | PHASE2 |
| NCT04803318 | RECRUITING | Solid Tumor, Adult; Hepatocellular Carcinoma |
Second Affiliated Hospital of Guangzhou Medical University |
2021-01-01 | PHASE2 |
| NCT07160361 | NOT_YET_RECRUITING | Carcinoma, Hepatocellular |
Second Affiliated Hospital of Xi'an Jiaotong University |
2025-10-01 | PHASE4 |
| NCT07790419 | NOT_YET_RECRUITING | Liver Cancer |
Zhai Wenlong |
2026-08-30 | PHASE4 |
| NCT07518706 | NOT_YET_RECRUITING | HCC - Hepatocellular Carcinoma |
Tianjin Medical University Cancer Institute and Hospital |
2026-04-30 | PHASE2 |
| NCT06682780 | RECRUITING | Advanced Solid Tumor |
LaNova Medicines Limited |
2025-09-17 | PHASE1; PHASE2 |
| NCT07177716 | NOT_YET_RECRUITING | Cervical Cancer |
L & L Bio Co., Ltd., Ningbo, China |
2025-10 | PHASE2; PHASE3 |
| NCT06673628 | RECRUITING | Angiosarcoma of Skin; Angiosarcoma Metastatic |
National Cancer Center, Japan |
2024-12-01 | PHASE2 |
| NCT07619950 | NOT_YET_RECRUITING | Neoplasms of Bone and Articular Cartilage With Unspecified Anatomical Site |
Yonsei University |
2026-07-01 | PHASE2 |
| NCT07680088 | NOT_YET_RECRUITING | Anal Squamous Cell Carcinoma |
University of Texas Southwestern Medical Center |
2026-09-30 | PHASE2 |
| NCT07540832 | NOT_YET_RECRUITING | Advanced Hepatocellular Carcinoma (HCC) |
Zhejiang Haichang Biotech Co., Ltd. |
2026-09 | PHASE1; PHASE2 |
| NCT07801287 | RECRUITING | HCC - Hepatocellular Carcinoma |
Tianjin Medical University Cancer Institute and Hospital |
2026-09-01 | PHASE2 |
| NCT07741617 | NOT_YET_RECRUITING | Urologic Neoplasms |
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School |
2026-08-15 | PHASE2 |
| NCT05185739 | RECRUITING | Hepatocellular Carcinoma |
University College, London |
2022-08-25 | PHASE2 |
| NCT07047586 | RECRUITING | Hepatocellular Carcinoma (HCC) |
Fudan University |
2025-07-02 | PHASE2 |
| NCT06192797 | RECRUITING | Cholangiocarcinoma Non-resectable |
Tongji Hospital |
2024-06-04 | PHASE2 |
| NCT05327686 | RECRUITING | Metastatic Renal Cell Carcinoma; Stage III Renal Cell Cancer AJCC v8; Stage IV Renal Cell Cancer AJCC v8; Unresectable Renal Cell Carcinoma |
NRG Oncology |
2023-02-01 | PHASE2 |
| NCT05170438 | ACTIVE_NOT_RECRUITING | Advanced Biliary Tract Cancer |
National Health Research Institutes, Taiwan |
2022-07-01 | PHASE2 |
| NCT07514429 | NOT_YET_RECRUITING | Carcinoma, Hepatocellular; Lenvatinib; Treatment Failure |
Ju Hyun Shim |
2026-03-15 | PHASE2 |
| NCT07297654 | NOT_YET_RECRUITING | Advanced Hepatocellular Carcinoma |
National Cancer Center, Korea |
2026-02 | PHASE2 |
| NCT07493668 | RECRUITING | Hepatocellular Carcinoma (HCC) |
CHA University |
2026-05-14 | PHASE2 |
| NCT05733715 | RECRUITING | Renal Cell Carcinoma |
Abramson Cancer Center at Penn Medicine |
2023-05-03 | EARLY_PHASE1 |
| NCT07263360 | NOT_YET_RECRUITING | BTC |
Tianjin Medical University Cancer Institute and Hospital |
2026-02-01 | PHASE2 |
| NCT03950609 | ACTIVE_NOT_RECRUITING | Advanced Carcinoid Tumor; Digestive System Neuroendocrine Neoplasm; Multiple Endocrine Neoplasia Type 1; Neuroendocrine Neoplasm; Unresectable Carcinoid Tumor |
M.D. Anderson Cancer Center |
2019-07-30 | PHASE2 |
| NCT07487662 | NOT_YET_RECRUITING | Hepato Cellular Carcinoma (HCC) |
Sun Yat-sen University |
2026-03-18 | PHASE2 |
| NCT07417501 | NOT_YET_RECRUITING | Solid Tumors |
Tongji Hospital |
2026-03-01 | PHASE2 |
| NCT05064280 | RECRUITING | Brain Metastases; Tumor |
M.D. Anderson Cancer Center |
2022-01-20 | PHASE2 |
| NCT05746208 | RECRUITING | Neuroendocrine Tumors; Well-Differentiated Neuroendocrine Carcinoma; High Grade Neuroendocrine Carcinoma, Any Site |
University of California, San Francisco |
2023-07-17 | PHASE2 |
| NCT06880523 | RECRUITING | Hepatocellular Carcinoma |
Canadian Cancer Trials Group |
2025-10-21 | PHASE2 |
| NCT06311929 | RECRUITING | HCC |
Chen Xiaoping |
2024-04-01 | PHASE4 |
| NCT06311942 | RECRUITING | HCC |
Chen Xiaoping |
2024-04-01 | PHASE4 |
| NCT05273554 | ACTIVE_NOT_RECRUITING | Tumor; Adenocarcinoma |
M.D. Anderson Cancer Center |
2022-08-31 | PHASE1 |
| NCT07010393 | NOT_YET_RECRUITING | Thyroid Neoplasms |
Fujian Medical University |
2025-07-01 | PHASE4 |
| NCT06849492 | NOT_YET_RECRUITING | Advanced Triple Negative Breast Cancer |
Fudan University |
2025-04-01 | PHASE2 |
| NCT07096609 | RECRUITING | GIST |
Asan Medical Center |
2025-10-29 | PHASE1; PHASE2 |
| NCT06409637 | NOT_YET_RECRUITING | Liver Cancer; Liver Transplant |
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University |
2025-01-01 | PHASE1; PHASE2 |
| NCT07389629 | RECRUITING | Iparomlimab and Tuvonralimab; Clear Cell Renal Cell Carcinoma; Neoadjuvant Therapy |
Sun Yat-sen University |
2025-11-21 | PHASE2 |
| NCT06311916 | NOT_YET_RECRUITING | HCC |
Chen Xiaoping |
2024-05-01 | PHASE4 |
| NCT07353073 | NOT_YET_RECRUITING | Head and Neck Mucosal Melanomas |
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University |
2026-01-01 | PHASE2 |
| NCT07480382 | NOT_YET_RECRUITING | Initially Unresectable Hepatocellular Carcinoma |
Hong Wu |
2026-04-01 | |
| NCT04645602 | RECRUITING | Human Papilloma Virus; Recurrent Respiratory Papillomatosis; Pulmonary Disease |
Yale University |
2025-07-18 | PHASE2 |
| NCT05077215 | NOT_YET_RECRUITING | Advanced Endometrial Cancer |
Evergreen Therapeutics, Inc. |
2026-12 | PHASE3 |
| NCT07256223 | NOT_YET_RECRUITING | Clear Cell Renal Cell Cancer (ccRCC); Liver Metastasis |
Fudan University |
2025-12-01 | PHASE2 |
| NCT06110793 | RECRUITING | Metastatic Breast Cancer |
Memorial Sloan Kettering Cancer Center |
2023-12-29 | PHASE1; PHASE2 |
| NCT05903833 | RECRUITING | Recurrent Vulvar Cancer; Persistent Vulvar Cancer; Metastatic Vulva Cancer; Locally Advanced Vulvar Cancer |
AGO Research GmbH |
2025-06-24 | PHASE2 |
| NCT05012371 | ACTIVE_NOT_RECRUITING | Advanced Clear Cell Renal Cell Carcinoma; Metastatic Clear Cell Renal Cell Carcinoma; Stage III Renal Cell Cancer AJCC v8; Stage IV Renal Cell Cancer AJCC v8 |
M.D. Anderson Cancer Center |
2022-02-16 | PHASE2 |
| NCT02861573 | ACTIVE_NOT_RECRUITING | Metastatic Castration-Resistant Prostate Cancer |
Merck Sharp & Dohme LLC |
2016-11-17 | PHASE1; PHASE2 |
| NCT06232564 | ACTIVE_NOT_RECRUITING | Neuroendocrine Tumors |
Imperial College London |
2024-07-08 | PHASE2 |
| NCT07776080 | NOT_YET_RECRUITING | HCC - Hepatocellular Carcinoma |
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology |
2026-10-01 | PHASE2 |
| NCT06762782 | RECRUITING | Hepatocellular Carcinoma (HCC); Adjuvant Therapy in Patients with Hepatocellular Carcinoma (HCC) At High Risk of Recurrence After Curative Resection or Ablation |
The First Affiliated Hospital with Nanjing Medical University |
2025-02 | PHASE2 |
| NCT06884982 | NOT_YET_RECRUITING | HCC - Hepatocellular Carcinoma |
Northern Jiangsu People's Hospital |
2025-03-13 | PHASE2 |
| NCT07359053 | RECRUITING | Sarcoma |
Shanghai 6th People's Hospital |
2025-12-25 | PHASE2 |
| NCT02925234 | RECRUITING | Cancer; Tumors; Neoplasm; Neoplasia |
The Netherlands Cancer Institute |
2016-08 | PHASE2 |
| NCT07110064 | RECRUITING | Advance Pancreatic Cancer |
Du Juan |
2025-09-03 | PHASE2 |
| NCT04171622 | ACTIVE_NOT_RECRUITING | Metastatic Thyroid Gland Carcinoma; Poorly Differentiated Thyroid Gland Carcinoma; Stage IVB Thyroid Gland Anaplastic Carcinoma AJCC v8; Stage IVC Thyroid Gland Anaplastic Carcinoma AJCC v8; Thyroid Gland Squamous Cell Carcinoma; Unresectable Thyroid Gland Carcinoma |
M.D. Anderson Cancer Center |
2021-11-04 | PHASE2 |
| NCT05181033 | RECRUITING | Breast Cancer |
National University Hospital, Singapore |
2021-12-27 | PHASE2 |
| NCT05985798 | RECRUITING | Hepatocellular Carcinoma Non-resectable |
Second Affiliated Hospital of Guangzhou Medical University |
2023-08-01 | PHASE3 |
| NCT07149090 | RECRUITING | STOMACH NEOPLASM; Gastric Cancer; Gastric Cancer Adenocarcinoma Metastatic |
Asan Medical Center |
2025-11-11 | PHASE1; PHASE2 |
| NCT05384015 | ACTIVE_NOT_RECRUITING | Small Cell Lung Cancer Extensive Stage |
Fundación GECP |
2022-11-07 | PHASE2 |
| NCT06748508 | NOT_YET_RECRUITING | Gastric (Stomach) Cancer |
Fudan University |
2024-12-25 | PHASE2 |
| NCT07097935 | RECRUITING | Advanced Clear Cell Renal Cell Carcinoma |
Jiangsu Hansoh Pharmaceutical Co., Ltd. |
2025-07-10 | PHASE1; PHASE2 |
| NCT06041477 | RECRUITING | Hepatocellular Carcinoma; Chemotherapy Effect; Chemotherapeutic Toxicity |
Sun Yat-sen University |
2023-10-31 | PHASE3 |
| NCT04427293 | ACTIVE_NOT_RECRUITING | Triple Negative Breast Cancer |
University of Illinois at Chicago |
2020-07-09 | PHASE1 |
| NCT07350070 | NOT_YET_RECRUITING | HCC; Liver Cirrhosis; Portal Hypertension |
Tongji Hospital |
2025-12-31 | PHASE2 |
| NCT06848920 | NOT_YET_RECRUITING | Differentiated Thyroid Carcinoma (DTC); Neoadjuvant Therapy |
Zhejiang University |
2025-03-01 | PHASE2 |
| NCT06963060 | ENROLLING_BY_INVITATION | Gallbladder Cancer; Cholangiocarcinoma |
Wei Gong |
2024-06-01 | PHASE2 |
| NCT05030506 | ACTIVE_NOT_RECRUITING | Renal Cell Carcinoma |
Merck Sharp & Dohme LLC |
2021-10-13 | PHASE1 |
| NCT06904014 | RECRUITING | HCC |
Lei ZHAO |
2023-10-25 | PHASE2 |
| NCT07282184 | RECRUITING | Hepotacellular Carcinoma |
Tongji Hospital |
2025-10-26 | PHASE1; PHASE2 |
| NCT05319730 | RECRUITING | Esophageal Squamous Cell Carcinoma |
Merck Sharp & Dohme LLC |
2023-05-16 | PHASE1; PHASE2 |
| NCT05774899 | RECRUITING | Adenoid Cystic Carcinoma; Metastatic Adenoid Cystic Carcinoma; Recurrent Adenoid Cystic Carcinoma |
Glenn J. Hanna |
2023-06-01 | PHASE1; PHASE2 |
| NCT06896396 | NOT_YET_RECRUITING | Unresectable Hepatocellular Carcinoma |
Zhiyong Huang |
2025-04-01 | PHASE1; PHASE2 |
| NCT07159217 | NOT_YET_RECRUITING | Biliary Tract Cancer; Disitamab Vedotin; Lenvatinib; Immune Checkpoint Inhibitors |
Peking Union Medical College Hospital |
2025-08-30 | PHASE2 |
| NCT05342194 | RECRUITING | Intrahepatic Cholangiocarcinoma |
Shanghai Junshi Bioscience Co., Ltd. |
2023-06-19 | PHASE3 |
| NCT07014150 | RECRUITING | Hepatocellular Carcinoma Resectable |
Peking Union Medical College Hospital |
2025-06-10 | PHASE2 |
| NCT06389500 | NOT_YET_RECRUITING | Biliary Tract Cancer |
Harbin Medical University |
2024-05-01 | PHASE2 |
| NCT06919848 | NOT_YET_RECRUITING | Biliary Tract Cancer (BTC) |
Fudan University |
2025-05-01 | PHASE2 |
| NCT05738616 | RECRUITING | Advanced Hepatocellular Carcinoma |
Wen Tianfu |
2024-05-10 | PHASE3 |
| NCT06986785 | RECRUITING | Advanced Hepatocellular Carcinoma |
Sichuan Baili Pharmaceutical Co., Ltd. |
2025-06-24 | PHASE2 |
| NCT06962787 | RECRUITING | Renal Cancer |
Sichuan Baili Pharmaceutical Co., Ltd. |
2025-07-28 | PHASE2 |
| NCT02780310 | ACTIVE_NOT_RECRUITING | Adenoid Cystic Carcinoma |
Memorial Sloan Kettering Cancer Center |
2016-05-19 | PHASE2 |
| NCT07530445 | RECRUITING | Second-Line Therapy for Unresectable or Metastatic Biliary Tract Cancer |
Sun Yat-sen University |
2026-03-23 | PHASE2 |
| NCT07356466 | ENROLLING_BY_INVITATION | Gastric (Stomach) Cancer |
Fujian Medical University |
2025-05-01 | EARLY_PHASE1 |
| NCT07670273 | RECRUITING | Biliary Tract Neoplasms Immunotherapy |
Peking Union Medical College Hospital |
2026-04-29 | PHASE2 |
| NCT07188311 | RECRUITING | Hepatoblastoma; Pediatric Cancer |
Sun Yat-sen University |
2025-04-10 | |
| NCT06648525 | NOT_YET_RECRUITING | Intrahepatic Cholangiocarcinoma (Icc) |
Harbin Medical University |
2024-10 | PHASE2 |
| NCT05901194 | ACTIVE_NOT_RECRUITING | Hepatocellular Carcinoma Non-resectable |
Assistance Publique - Hôpitaux de Paris |
2024-07-10 | PHASE1; PHASE2 |
| NCT04008797 | ACTIVE_NOT_RECRUITING | Endometrial Neoplasms; Neoplasms; Carcinoma, Hepatocellular; Liver Neoplasms; Colorectal Neoplasms |
Eisai Inc. |
2019-07-11 | PHASE1; PHASE2 |
| NCT04976634 | ACTIVE_NOT_RECRUITING | Neoplasm Malignant |
Merck Sharp & Dohme LLC |
2021-08-18 | PHASE2 |
| NCT06860477 | RECRUITING | Intrahepatic Cholangiocellular Carcinoma |
Fudan University |
2025-03-18 | PHASE2 |
| NCT05106127 | NOT_YET_RECRUITING | Advanced Endometrial Cancer |
Evergreen Therapeutics, Inc. |
2026-08 | PHASE2 |
| NCT04784247 | ACTIVE_NOT_RECRUITING | Advanced Sarcoma |
Memorial Sloan Kettering Cancer Center |
2021-03-18 | PHASE2 |
| NCT05718232 | NOT_YET_RECRUITING | Advanced Hepatocellular Carcinoma |
Sun Yat-sen University |
2023-03 | PHASE3 |
| NCT02562118 | ACTIVE_NOT_RECRUITING | Breast Cancer |
National University Hospital, Singapore |
2015-10-02 | PHASE1; PHASE2 |
| NCT05286437 | ACTIVE_NOT_RECRUITING | Hormone Receptor-Positive HER2-Negative Advanced Breast Cancer |
National Cancer Centre, Singapore |
2023-02-15 | PHASE2 |
| NCT06739395 | RECRUITING | Solid Tumor; Precision Medicine |
Tianjin Medical University Second Hospital |
2024-11-01 | PHASE2 |
| NCT04523493 | ACTIVE_NOT_RECRUITING | Advanced Hepatocellular Carcinoma (HCC) |
Shanghai Junshi Bioscience Co., Ltd. |
2020-06-29 | PHASE3 |
| NCT05617859 | RECRUITING | Effectiveness; Sexuality |
Henan Cancer Hospital |
2023-04-30 | PHASE2 |
| NCT05823311 | RECRUITING | Advanced Cholangiocarcinoma |
Second Affiliated Hospital, Zhejiang University, School of Medicine |
2023-09-01 | PHASE3 |
| NCT06195228 | RECRUITING | Advanced Thyroid Cancer Patients Who Received Target Therapy |
Fudan University |
2020-01-01 | PHASE4 |
| NCT05041153 | ACTIVE_NOT_RECRUITING | Advanced Gastric Adenocarcinoma; Advanced Gastroesophageal Junction Adenocarcinoma; Clinical Stage III Gastric Cancer AJCC v8; Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8; Clinical Stage IV Gastric Cancer AJCC v8; Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8; Clinical Stage IVA Gastric Cancer AJCC v8; Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8; Clinical Stage IVB Gastric Cancer AJCC v8; Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8; Metastatic Gastric Adenocarcinoma; Metastatic Gastroesophageal Junction Adenocarcinoma; Pathologic Stage III Gastric Cancer AJCC v8; Pathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8; Pathologic Stage IIIA Gastric Cancer AJCC v8; Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8; Pathologic Stage IIIB Gastric Cancer AJCC v8; Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8; Pathologic Stage IIIC Gastric Cancer AJCC v8; Pathologic Stage IV Gastric Cancer AJCC v8; Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8; Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8; Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8; Postneoadjuvant Therapy Stage III Gastric Cancer AJCC v8; Postneoadjuvant Therapy Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8; Postneoadjuvant Therapy Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8; Postneoadjuvant Therapy Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8; Postneoadjuvant Therapy Stage IV Gastric Cancer AJCC v8; Postneoadjuvant Therapy Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8; Postneoadjuvant Therapy Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8; Postneoadjuvant Therapy Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8; Unresectable Gastric Adenocarcinoma; Unresectable Gastroesophageal Junction Adenocarcinoma |
M.D. Anderson Cancer Center |
2022-02-14 | EARLY_PHASE1 |
| NCT05147558 | ACTIVE_NOT_RECRUITING | Uterine Carcinosarcoma; Advanced Uterine Carcinosarcoma |
Memorial Sloan Kettering Cancer Center |
2021-12-23 | PHASE2 |
| NCT06524466 | ACTIVE_NOT_RECRUITING | Resectable Hepatocellular Carcinoma; Macrovascular Invasion; CNLC IIIA Stage |
Sun Yat-sen University |
2024-07-23 | PHASE2 |
| NCT06622031 | RECRUITING | Hepatocellular Carcinoma; Portal Vein Tumor Thrombus; Systemic Therapy |
Sun Yat-sen University |
2024-10-01 | |
| NCT04615143 | RECRUITING | Recurrent Hepatocellular Carcinoma |
Sun Yat-sen University |
2020-12-01 | PHASE2 |
| NCT04209660 | ACTIVE_NOT_RECRUITING | Adenoid Cystic Carcinoma; Salivary Gland Cancer |
Memorial Sloan Kettering Cancer Center |
2020-06-02 | PHASE2 |
| NCT07535840 | NOT_YET_RECRUITING | HCC - Hepatocellular Carcinoma; TP53 Gene Mutation; Unresectable; Resistant Cancer |
Tongji Hospital |
2026-05 | |
| NCT06892925 | ACTIVE_NOT_RECRUITING | Biliary Tract Tumors |
Eastern Hepatobiliary Surgery Hospital |
2025-06-14 | PHASE2 |
| NCT06984718 | NOT_YET_RECRUITING | HCC; Hepatocellular Carcinoma |
Akeso |
2025-06-25 | PHASE2 |
| NCT05033522 | SUSPENDED | Hepatocellular Carcinoma |
Mirror Biologics, Inc. |
2023-08-01 | PHASE2; PHASE3 |
| NCT06138769 | ACTIVE_NOT_RECRUITING | Hepatocellular Carcinoma |
Asan Medical Center |
2023-07-20 | PHASE2 |
| NCT05822752 | ACTIVE_NOT_RECRUITING | Hepatocellular Carcinoma |
AbbVie |
2023-09-21 | PHASE2 |
| NCT05621499 | ACTIVE_NOT_RECRUITING | Hepatocellular Carcinoma |
Tianjin Medical University Cancer Institute and Hospital |
2022-12-20 | |
| NCT05608200 | RECRUITING | Hepatocellular Carcinoma Non-resectable |
Second Affiliated Hospital of Guangzhou Medical University |
2022-11-02 | PHASE3 |
| NCT07501351 | RECRUITING | Hepatocellulcar Carcinoma |
Sun Yat-sen University |
2026-01-05 | PHASE2 |
| NCT06266338 | RECRUITING | Cervix Cancer; Cervical Cancer |
University of Texas Southwestern Medical Center |
2024-03-11 | PHASE2 |
| NCT05608213 | RECRUITING | Hepatocellular Carcinoma Non-resectable |
Second Affiliated Hospital of Guangzhou Medical University |
2022-11-02 | PHASE3 |
| NCT05775159 | ACTIVE_NOT_RECRUITING | Hepatocellular Carcinoma; Biliary Tract Cancer |
AstraZeneca |
2023-04-24 | PHASE2 |
| NCT04770896 | ACTIVE_NOT_RECRUITING | Unresectable Hepatocellular Carcinoma |
Hoffmann-La Roche |
2021-04-26 | PHASE3 |
| NCT05973903 | WITHDRAWN | GBM |
Tel Aviv Medical Center |
2024-06-01 | PHASE1; PHASE2 |
| NCT07282262 | RECRUITING | Biliary Tract Cancer |
Peking Union Medical College Hospital |
2024-05-01 | PHASE2 |
| NCT07408804 | RECRUITING | Unresectable Hepatocellular Carcinoma (HCC) |
Bangladesh Medical University |
2025-04-08 | |
| NCT07131501 | NOT_YET_RECRUITING | Hepatocellular Carcinoma; Immunotherapy; Preoperative; PD-1; CTLA-4 |
The First Affiliated Hospital with Nanjing Medical University |
2025-08-11 | PHASE2 |
| NCT05286320 | NOT_YET_RECRUITING | Unresectable Hepatocellular Carcinoma; Pembrolizumab; Lenvatinib; Stereotactic Body Radiotherapy |
National Taiwan University Hospital |
2023-03-01 | PHASE1; PHASE2 |
| NCT05057845 | RECRUITING | Advanced Hepatocellular Carcinoma |
Fudan University |
2021-09-26 | PHASE2 |
| NCT06859684 | RECRUITING | Intrahepatic Cholangiocarcinoma (Icc); HAIC; Durvalumab |
West China Hospital |
2025-03-01 | PHASE2 |
| NCT06852287 | RECRUITING | Intrahepatic Cholangiocarcinoma (Icc); Gall Bladder Cancer |
Tianjin Medical University Cancer Institute and Hospital |
2024-09-01 | PHASE2 |
| NCT06794073 | RECRUITING | Carcinoma, Hepatocellular; Neoplasms, Glandular and Epithelial; Adenocarcinoma; Digestive System Neoplasms; Liver Neoplasms |
Shanghai Zhongshan Hospital |
2026-01-31 | |
| NCT07077798 | NOT_YET_RECRUITING | Hepatocellular Carcinoma (HCC) |
Wan-Guang Zhang |
2025-08-01 | |
| NCT07150377 | NOT_YET_RECRUITING | Hepatocellular Carcinoma (HCC) |
The Second Affiliated Hospital of Shandong First Medical University |
2025-08-24 | PHASE2 |
| NCT04626518 | ACTIVE_NOT_RECRUITING | Carcinoma, Renal Cell |
Merck Sharp & Dohme LLC |
2020-12-17 | PHASE1; PHASE2 |
| NCT04626479 | ACTIVE_NOT_RECRUITING | Carcinoma, Renal Cell |
Merck Sharp & Dohme LLC |
2020-12-16 | PHASE1; PHASE2 |
| NCT07159204 | ACTIVE_NOT_RECRUITING | Biliary Tract Cancer (BTC) |
Peking Union Medical College Hospital |
2024-08-07 | PHASE2 |
| NCT06550921 | RECRUITING | Advanced Hepatocellular Carcinoma; Oligometastasis; Ablation; Anti-PD1 Antibody; Lenvatinib |
Sun Yat-sen University |
2024-08-01 | |
| NCT04745988 | ACTIVE_NOT_RECRUITING | Gastric Cancer |
National Cancer Center Hospital East |
2021-11-11 | PHASE2 |
| NCT06157996 | RECRUITING | Gastric Cancer |
Nanfang Hospital, Southern Medical University |
2024-06-01 | PHASE2 |
| NCT06492395 | RECRUITING | Hepatocellular Carcinoma Non-resectable |
Second Affiliated Hospital of Guangzhou Medical University |
2024-08-01 | PHASE3 |
| NCT06034977 | UNKNOWN | Hepatocellular Carcinoma |
Chang Gung Memorial Hospital |
2023-12-01 | PHASE2 |
| NCT04039607 | COMPLETED | Hepatocellular Carcinoma |
Bristol-Myers Squibb |
2019-09-30 | PHASE3 |
| NCT06383559 | UNKNOWN | Gastric Cancer |
Tianjin Medical University Cancer Institute and Hospital |
2023-12-01 | PHASE2 |
| NCT04865887 | RECRUITING | Cervical Cancer; Metastatic Cervical Cancer |
Georgetown University |
2022-10-07 | PHASE2 |
| NCT06746961 | NOT_YET_RECRUITING | Esophageal Squamous Cell Carcinoma (ESCC) |
The First Affiliated Hospital of Zhengzhou University |
2025-01 | PHASE1; PHASE2 |
| NCT05319015 | RECRUITING | Renal Cell Carcinoma |
University of Texas Southwestern Medical Center |
2023-01-06 | PHASE2 |
| NCT06318286 | ACTIVE_NOT_RECRUITING | Malignant Pleural Mesothelioma |
Hyogo Medical University |
2024-03-13 | PHASE2 |
| NCT06261125 | RECRUITING | Hepatocellular Carcinoma |
Mian XI |
2024-03-10 | PHASE2 |
| NCT07482059 | RECRUITING | Unresectable Hepatocellular Carcinoma |
West China Hospital |
2026-02 | PHASE1; PHASE2 |
| NCT05171335 | ENROLLING_BY_INVITATION | Hepatocellular Carcinoma |
The Methodist Hospital Research Institute |
2022-06-20 | PHASE2 |
| NCT05168163 | RECRUITING | Locally Advanced Hepatocellular Carcinoma; Metastatic Hepatocellular Carcinoma; Stage III Hepatocellular Carcinoma AJCC v8; Stage IIIA Hepatocellular Carcinoma AJCC v8; Stage IIIB Hepatocellular Carcinoma AJCC v8; Stage IV Hepatocellular Carcinoma AJCC v8; Stage IVA Hepatocellular Carcinoma AJCC v8; Stage IVB Hepatocellular Carcinoma AJCC v8; Unresectable Hepatocellular Carcinoma |
Academic and Community Cancer Research United |
2022-05-27 | PHASE2 |
| NCT05188118 | COMPLETED | Renal Cell Carcinoma |
Icahn School of Medicine at Mount Sinai |
2023-02-15 | EARLY_PHASE1 |
| NCT07157969 | RECRUITING | HCC - Hepatocellular Carcinoma |
Peking Union Medical College Hospital |
2025-02-19 | PHASE2 |
| NCT06361758 | WITHDRAWN | Hepatocellular Carcinoma |
Shanghai Zhongshan Hospital |
2024-05-31 | PHASE2 |
| NCT04164199 | COMPLETED | Advanced Malignancies |
BeOne Medicines |
2019-12-19 | PHASE3 |
| NCT06563934 | NOT_YET_RECRUITING | Liver Cancer |
Xu Yong, MD |
2024-08-30 | PHASE2 |
| NCT04305054 | COMPLETED | Melanoma |
Merck Sharp & Dohme LLC |
2020-07-01 | PHASE1; PHASE2 |
| NCT05155189 | RECRUITING | Hepatocellular Carcinoma |
Zhejiang University |
2022-02-21 | PHASE1 |
| NCT05797805 | RECRUITING | Advanced Hepatocellular Carcinoma |
Iterion Therapeutics |
2023-09-13 | PHASE1; PHASE2 |
| NCT05545969 | WITHDRAWN | Mucosal Melanoma |
Melanoma Institute Australia |
2024-03 | PHASE2 |
| NCT05585580 | ACTIVE_NOT_RECRUITING | Advanced Gastric or Gastroesophageal Junction Adenocarcinoma |
Qilu Hospital of Shandong University |
2023-03-01 | PHASE2 |
| NCT06406634 | RECRUITING | Hepatocellular Carcinoma |
Hunan Cancer Hospital |
2024-05-15 | PHASE2 |
| NCT06374602 | RECRUITING | Anaplastic Thyroid Cancer |
Saint Petersburg State University, Russia |
2024-03-25 | PHASE2 |
| NCT04887805 | ACTIVE_NOT_RECRUITING | Advanced Pancreatic Ductal Adenocarcinoma; Stage II Pancreatic Cancer AJCC v8; Stage IIA Pancreatic Cancer AJCC v8; Stage IIB Pancreatic Cancer AJCC v8; Stage III Pancreatic Cancer AJCC v8; Stage IV Pancreatic Cancer AJCC v8; Unresectable Pancreatic Ductal Adenocarcinoma |
City of Hope Medical Center |
2021-07-21 | PHASE2 |
| NCT05301842 | ACTIVE_NOT_RECRUITING | Hepatocellular Carcinoma |
AstraZeneca |
2022-03-28 | PHASE3 |
| NCT05081180 | TERMINATED | Central Nervous System Tumors |
EMD Serono Research & Development Institute, Inc. |
2021-12-03 | PHASE1 |
| NCT05899049 | ACTIVE_NOT_RECRUITING | Carcinoma, Renal Cell |
Merck Sharp & Dohme LLC |
2022-07-27 | PHASE3 |
| NCT04736706 | ACTIVE_NOT_RECRUITING | Carcinoma, Renal Cell |
Merck Sharp & Dohme LLC |
2021-04-14 | PHASE3 |
| NCT04586231 | ACTIVE_NOT_RECRUITING | Carcinoma, Renal Cell |
Merck Sharp & Dohme LLC |
2021-02-25 | PHASE3 |
| NCT06114940 | TERMINATED | Renal Cell Carcinoma (RCC) |
Jinling Hospital, China |
2022-12-20 | PHASE2 |
| NCT05992584 | UNKNOWN | Hepatocellular Carcinoma |
Second Affiliated Hospital of Guangzhou Medical University |
2023-08-10 | PHASE2 |
| NCT05954897 | RECRUITING | Hepatocellular Carcinoma |
Guangdong Provincial People's Hospital |
2023-09-01 | PHASE2 |
| NCT05433116 | ACTIVE_NOT_RECRUITING | Head and Neck Squamous Cell Carcinoma |
Universität des Saarlandes |
2023-05-25 | PHASE2 |
| NCT06208462 | RECRUITING | Intrahepatic Cholangiocarcinoma |
The First Affiliated Hospital with Nanjing Medical University |
2024-01-19 | PHASE2 |
| NCT06129955 | UNKNOWN | Renal Cell Carcinoma |
Sun Yat-sen University |
2023-11-11 | PHASE2 |
| NCT06140576 | NOT_YET_RECRUITING | Breast Neoplasms |
Zhejiang Cancer Hospital |
2023-11-30 | PHASE1; PHASE2 |
| NCT05910970 | UNKNOWN | Hepatocellular Carcinoma; Recurrence; Immune Checkpoint Inhibitor |
Guangxi Medical University |
2024-02-15 | PHASE3 |
| NCT03899428 | RECRUITING | Hepatocellular Carcinoma |
Humanity & Health Medical Group Limited |
2019-05-02 | PHASE2 |
| NCT06364007 | UNKNOWN | Hepatocellular Carcinoma |
Sulai Liu |
2024-03-03 | PHASE2 |
| NCT05920863 | RECRUITING | Hepatocellular Carcinoma; Lenvatinib; Tislelizumab; TACE; Pharmorubicin; Oxaliplatin |
Zhejiang Cancer Hospital |
2023-07-01 | PHASE2 |
| NCT06463548 | NOT_YET_RECRUITING | Biliary Tract Carcinoma |
Yunpeng Liu |
2024-07-01 | |
| NCT06230471 | RECRUITING | Biliary Tract Neoplasms Immunotherapy |
Peking Union Medical College Hospital |
2023-01-09 | PHASE2 |
| NCT05078931 | ACTIVE_NOT_RECRUITING | NSCLC |
Shanghai Chest Hospital |
2021-10-27 | PHASE2 |
| NCT05835245 | UNKNOWN | Advanced Intrahepatic Cholangiocarcinoma |
Fudan University |
2023-04-28 | PHASE2 |
| NCT06740370 | RECRUITING | Hepatocellular Carcinoma; Transcatheter Arterial Chemoembolization; Anti-PD1 Antibody; Lenvatinib |
Sun Yat-sen University |
2024-12-13 | |
| NCT06253598 | NOT_YET_RECRUITING | Hepatocellular Carcinoma |
The First Affiliated Hospital of Bengbu Medical University |
2024-03-30 | PHASE2 |
| NCT05897268 | UNKNOWN | Hepatocellular Carcinoma |
Fudan University |
2023-06-20 | PHASE2 |
| NCT05893056 | UNKNOWN | Gastric Cancer Metastatic to Liver |
Fudan University |
2023-06-16 | PHASE2 |
| NCT05675462 | UNKNOWN | Hepatocellular Carcinoma |
Fudan University |
2023-03-01 | PHASE1 |
| NCT05823987 | UNKNOWN | Advanced Biliary Tract Cancer |
Fudan University |
2023-05-16 | PHASE2 |
| NCT05781074 | UNKNOWN | Advanced Biliary Tract Cancer |
Fudan University |
2023-03-23 | PHASE2 |
| NCT06032845 | RECRUITING | Solid Tumor, Adult |
Fudan University |
2023-09-13 | PHASE2 |
| NCT06519721 | ACTIVE_NOT_RECRUITING | Hepatocellular Carcinoma |
RenJi Hospital |
2024-08-06 | |
| NCT05342636 | COMPLETED | Esophageal Squamous Cell Carcinoma (ESCC) |
Merck Sharp & Dohme LLC |
2022-07-27 | PHASE1; PHASE2 |
| NCT05098847 | RECRUITING | Liver Metastasis |
Fudan University |
2021-10-29 | PHASE2 |
| NCT06371157 | RECRUITING | Hepatocellular Carcinoma |
Akeso |
2024-08-02 | PHASE3 |
| NCT05620134 | ACTIVE_NOT_RECRUITING | Cancer; Tumor, Solid; Advanced Solid Tumor; Metastatic Cancer; Melanoma; Colorectal Cancer; Non-small Cell Lung Cancer; Small-cell Lung Cancer; Urothelial Carcinoma; Squamous Cell Carcinoma of Head and Neck; Luminal Breast Cancer; Triple Negative Breast Cancer; Clear Cell Renal Cell Carcinoma; Papillary Renal Cell Carcinoma; Gastric Adenocarcinoma; GastroEsophageal Cancer; Squamous Cell Carcinoma Skin; Pancreatic Adenocarcinoma; Hepatocellular Carcinoma; Colorectal Adenocarcinoma; Epithelial Ovarian Cancer; Thyroid Cancer |
Salubris Biotherapeutics Inc |
2022-10-17 | PHASE1; PHASE2 |
| NCT04700072 | COMPLETED | Melanoma |
Merck Sharp & Dohme LLC |
2021-05-03 | PHASE1; PHASE2 |
| NCT03564691 | COMPLETED | Neoplasms |
Merck Sharp & Dohme LLC |
2018-07-11 | PHASE1 |
| NCT04522323 | ACTIVE_NOT_RECRUITING | Advanced Renal Cell Carcinoma |
MedImmune LLC |
2020-08-05 | PHASE1 |
| NCT04869137 | ACTIVE_NOT_RECRUITING | Merkel Cell Carcinoma; Neuroendocrine Carcinoma of the Skin; Trabecular Carcinoma of the Skin |
H. Lee Moffitt Cancer Center and Research Institute |
2021-05-28 | PHASE2 |
| NCT05696548 | ACTIVE_NOT_RECRUITING | Anaplastic Thyroid Cancer |
National Cancer Center Hospital East |
2019-07-02 | PHASE2 |
| NCT03573960 | COMPLETED | Thyroid Neoplasms |
Eisai Pharmaceuticals India Pvt. Ltd |
2018-04-01 | PHASE4 |
| NCT05532059 | RECRUITING | Advanced Cholangiocarcinoma |
Second Affiliated Hospital, Zhejiang University, School of Medicine |
2022-01-31 | PHASE2 |
| NCT04305041 | COMPLETED | Melanoma |
Merck Sharp & Dohme LLC |
2020-06-26 | PHASE1; PHASE2 |
| NCT05010681 | RECRUITING | Intrahepatic Cholangiocarcinoma |
Fudan University |
2021-08-24 | PHASE2 |
| NCT04246177 | TERMINATED | Carcinoma, Hepatocellular |
Merck Sharp & Dohme LLC |
2020-05-22 | PHASE3 |
| NCT05007106 | COMPLETED | Uterine Cervical Neoplasms; Endometrial Neoplasms; Squamous Cell Carcinoma of Head and Neck; Gallbladder Neoplasms; Cholangiocarcinoma; Esophageal Neoplasms; Triple Negative Breast Neoplasms; Hepatocellular Carcinoma; Urinary Bladder Neoplasms; Ovarian Neoplasms; Stomach Neoplasms |
Merck Sharp & Dohme LLC |
2021-09-16 | PHASE2 |
| NCT07537985 | COMPLETED | Hepatocellulcar Carcinoma |
Sun Yat-sen University |
2020-01-01 | |
| NCT05408221 | UNKNOWN | Hepatocellular Carcinoma |
Shandong New Time Pharmaceutical Co., LTD |
2022-11-11 | PHASE2; PHASE3 |
| NCT05824481 | ACTIVE_NOT_RECRUITING | Endometrial Cancer; Endometrial Adenocarcinoma |
Sun Yat-sen University |
2023-05-08 | PHASE2 |
| NCT06201065 | RECRUITING | Hepatocellular Carcinoma |
Sun Yat-sen University |
2023-12-26 | PHASE3 |
| NCT04550624 | COMPLETED | Advanced Biliary Tract Carcinoma |
Shanghai Jiahui International Hospital |
2021-09-15 | PHASE2 |
| NCT06161558 | WITHDRAWN | Neoplasms |
National Cancer Institute (NCI) |
2025-07-15 | PHASE1 |
| NCT05444478 | RECRUITING | Hepatocellular Carcinoma; Microwave Ablation; Liver Cancer; Lenvatinib; Recurrent Tumor |
Sun Yat-sen University |
2022-07-01 | |
| NCT06210334 | UNKNOWN | Hepatocellular Carcinoma With PVTT |
Li Xiao Wei |
2024-03 | PHASE2 |
| NCT06463444 | UNKNOWN | HCC; Precision Therapy |
Chen Xiaoping |
2024-06-01 | PHASE1 |
| NCT05101629 | COMPLETED | Hepatocellular Carcinoma |
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest |
2022-05-11 | PHASE2 |
| NCT06061276 | RECRUITING | Liver Diseases; Hepatocellular Carcinoma; Immunotherapy; Camrelizumab; Lenvatinib |
Sun Yat-sen University |
2024-05-20 | |
| NCT04924101 | COMPLETED | Small Cell Lung Cancer |
Merck Sharp & Dohme LLC |
2021-07-15 | PHASE2 |
| NCT05113186 | ACTIVE_NOT_RECRUITING | Hepatocellular Carcinoma |
Assistance Publique - Hôpitaux de Paris |
2022-02-02 | PHASE2 |
| NCT04194775 | ACTIVE_NOT_RECRUITING | Hepatocellular Carcinoma |
CStone Pharmaceuticals |
2019-12-13 | PHASE3 |
| NCT05831969 | UNKNOWN | Advanced HCC |
Shenyang Tenth People's Hospital |
2023-06-05 | PHASE2 |
| NCT05897138 | NOT_YET_RECRUITING | Hepatocellular Carcinoma |
Fujian Cancer Hospital |
2023-08-01 | PHASE2 |
| NCT04955743 | TERMINATED | Melanoma; Renal Cell Carcinoma; Brain Metastases; PD1/PD-L1 Experienced; Pembrolizumab; Lenvatinib; Metastatic Melanoma |
Yale University |
2022-02-09 | PHASE2 |
| NCT04321954 | COMPLETED | Differentiated Thyroid Cancer; Advanced Cancer |
Massachusetts Eye and Ear Infirmary |
2021-03-09 | PHASE2 |
| NCT05103904 | TERMINATED | Recurrent Hepatocellular Carcinoma; Stage III Hepatocellular Carcinoma AJCC v8; Stage IIIA Hepatocellular Carcinoma AJCC v8; Stage IIIB Hepatocellular Carcinoma AJCC v8; Stage IV Hepatocellular Carcinoma AJCC v8; Stage IVA Hepatocellular Carcinoma AJCC v8; Stage IVB Hepatocellular Carcinoma AJCC v8; Unresectable Hepatocellular Carcinoma |
Emory University |
2022-04-19 | PHASE2 |
| NCT05903456 | UNKNOWN | Hepatocellular Carcinoma |
Zhejiang Cancer Hospital |
2023-07 | PHASE2 |
| NCT07184424 | COMPLETED | HCC - Hepatocellular Carcinoma |
Beijing Tsinghua Chang Gung Hospital |
2023-05-24 | |
| NCT04669496 | ACTIVE_NOT_RECRUITING | Intrahepatic Cholangiocarcinoma; PD1 Antibody; Lenvatinib; Gemox Chemotherapy |
Shanghai Zhongshan Hospital |
2021-01-20 | PHASE2; PHASE3 |
| NCT06417606 | UNKNOWN | Intrahepatic Cholangiocarcinoma |
Zhiyong Huang |
2024-05-30 | PHASE4 |
| NCT07304388 | COMPLETED | Intrahepatic Cholangiocarcinoma (Icc) |
Sun Yat-sen University |
2023-02-10 | PHASE2 |
| NCT05767684 | UNKNOWN | Refractory Tumor; Solid Tumor |
National Health Research Institutes, Taiwan |
2023-06-01 | PHASE1 |
| NCT06143579 | NOT_YET_RECRUITING | Potentially Resectable Hepatocellular Carcinoma |
Sun Yat-sen University |
2023-12-15 | PHASE2 |
| NCT05949424 | UNKNOWN | Renal Cell Carcinoma; Ovarian Carcinoma; Thyroid Carcinoma; Breast Carcinoma; Endometrium Carcinoma |
University Medical Center Groningen |
2024-05 | PHASE4 |
| NCT06298968 | RECRUITING | Intrahepatic Cholangiocarcinoma |
Nanfang Hospital, Southern Medical University |
2024-04-26 | PHASE2 |
| NCT06070636 | UNKNOWN | Liver Diseases; Hepatocellular Carcinoma; Immunotherapy; Lenvatinib; Sintilimab |
Sun Yat-sen University |
2024-05-20 | |
| NCT04704219 | COMPLETED | Renal Cell Carcinoma |
Merck Sharp & Dohme LLC |
2021-02-23 | PHASE2 |
| NCT04848337 | ACTIVE_NOT_RECRUITING | Prostate Cancer Metastatic; Neuroendocrine Tumors |
University of Michigan Rogel Cancer Center |
2021-05-25 | PHASE2 |
| NCT03781934 | COMPLETED | Hepatocellular Carcinoma; Intrahepatic Cholangiocarcinoma; Liver Metastases |
Medivir |
2018-09-05 | PHASE1; PHASE2 |
| NCT04319484 | UNKNOWN | Hepatocellular Carcinoma; Portal Vein Tumor Thrombus; Liver Transplantation |
RenJi Hospital |
2020-05-02 | PHASE2; PHASE3 |
| NCT06215651 | RECRUITING | Cadonilimab and Lenvatinib |
Peking Union Medical College Hospital |
2024-03-11 | PHASE2 |
| NCT06241105 | UNKNOWN | Recurrent Ovarian Carcinoma |
Peking Union Medical College Hospital |
2023-02-01 | PHASE2 |
| NCT06277024 | RECRUITING | Overall Response Rate |
Fujian Medical University |
2023-01-01 | |
| NCT04287829 | ACTIVE_NOT_RECRUITING | Mesotheliomas Pleural |
The Netherlands Cancer Institute |
2021-03-01 | PHASE2 |
| NCT05308901 | TERMINATED | Melanoma, Uveal |
Providence Health & Services |
2022-08-02 | PHASE2 |
| NCT06482086 | RECRUITING | Locally Advanced Thyroid Gland Carcinoma |
West China Hospital |
2021-06-01 | PHASE2 |
| NCT04951947 | RECRUITING | Small-cell Lung Cancer |
Hunan Province Tumor Hospital |
2023-06-01 | PHASE2 |
| NCT06327269 | RECRUITING | High Risk of Recurrence |
Chang Gung Memorial Hospital |
2021-04-01 | EARLY_PHASE1 |
| NCT06089382 | NOT_YET_RECRUITING | Hepatocellular Carcinoma |
Tongji Hospital |
2023-11-01 | PHASE3 |
| NCT05803928 | UNKNOWN | Hepatocellular Carcinoma |
Hua Li |
2024-01-01 | PHASE1 |
| NCT06030934 | UNKNOWN | Gastric / Gastroesophageal Junction Adenocarcinoma |
Fudan University |
2022-10-24 | PHASE2 |
| NCT03797326 | COMPLETED | Advanced Solid Tumors; Triple Negative Breast Cancer; Ovarian Cancer; Gastric Cancer; Colorectal Cancer; Glioblastoma; Biliary Tract Cancers; Pancreatic Cancer |
Merck Sharp & Dohme LLC |
2019-02-12 | PHASE2 |
| NCT05091346 | COMPLETED | Melanoma; Carcinoma, Hepatocellular; Colorectal Neoplasms |
Eisai Inc. |
2021-10-27 | PHASE1; PHASE2 |
| NCT04776148 | COMPLETED | Colorectal Neoplasms |
Merck Sharp & Dohme LLC |
2021-03-29 | PHASE3 |
| NCT05263492 | TERMINATED | Endometrial Cancer; Mismatch Repair-Proficient; Recurrent Endometrial Cancer |
Virginia Commonwealth University |
2022-04-01 | PHASE2 |
| NCT04393350 | ACTIVE_NOT_RECRUITING | Kidney Cancer; Stage III Renal Cell Cancer AJCC v8; Stage IV Renal Cell Cancer AJCC v8 |
Emory University |
2020-06-22 | PHASE2 |
| NCT05410197 | UNKNOWN | Advanced Biliary Tract Cancer |
Sun Yat-sen University |
2022-10-10 | PHASE2 |
| NCT04989322 | UNKNOWN | Nsclc; EGFR Activating Mutation; EGF-R Positive Non-Small Cell Lung Cancer; ALK Gene Rearrangement Positive; ROS1 Gene Rearrangement; ROS1 Positive NSCLC - Reactive Oxygen Species 1 Positive Non-Small Cell Lung Cancer |
Dr Joanne CHIU |
2021-10-05 | PHASE2 |
| NCT04443309 | UNKNOWN | Hepatocellular Carcinoma |
Peking Union Medical College Hospital |
2020-09-11 | PHASE1; PHASE2 |
| NCT05807776 | COMPLETED | Resectable Hepatocellular Carcinoma |
Tianjin Medical University Cancer Institute and Hospital |
2023-04-24 | PHASE2 |
| NCT05406466 | UNKNOWN | Melanoma |
Fudan University |
2022-07-15 | PHASE2 |
| NCT04710628 | COMPLETED | Metastatic Thymic Carcinoma; Thymoma Type B3 |
MedSIR |
2021-09-21 | PHASE2 |
| NCT06003673 | UNKNOWN | Hepatocellular Carcinoma Resectable |
First Affiliated Hospital of Fujian Medical University |
2023-07-01 | PHASE4 |
| NCT04211168 | UNKNOWN | Advanced Biliary Tract Cancer |
Peking Union Medical College Hospital |
2020-08-11 | PHASE2 |
| NCT04911959 | UNKNOWN | Hepatocellular Carcinoma; Lenvatinib |
Second Affiliated Hospital, Zhejiang University, School of Medicine |
2022-07-01 | PHASE1; PHASE2 |
| NCT04791176 | COMPLETED | Hepatocellular Carcinoma; Radiotherapy; Lenvatinib |
Cancer Institute and Hospital, Chinese Academy of Medical Sciences |
2021-04-12 | PHASE2 |
| NCT04428151 | COMPLETED | Squamous Cell Carcinoma of Head and Neck |
Merck Sharp & Dohme LLC |
2020-08-06 | PHASE2 |
| NCT05740215 | UNKNOWN | Solid Tumors |
Shandong New Time Pharmaceutical Co., LTD |
2022-05-23 | PHASE1; PHASE2 |
| NCT05215665 | UNKNOWN | Cholangiocarcinoma |
Tianjin Medical University Cancer Institute and Hospital |
2022-01-15 | |
| NCT04267120 | TERMINATED | Renal Cell Carcinoma |
Washington University School of Medicine |
2020-07-29 | PHASE2 |
| NCT06161558 | Not yet recruiting | Neoplasms |
National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) |
2024-05-15 | Phase 1 |
| NCT05303090 | COMPLETED | Pancreatic Ductal Adenocarcinoma |
Fudan University |
2022-03-31 | PHASE1 |
| NCT05842317 | UNKNOWN | Hepatocellular Carcinoma |
Peking Union Medical College Hospital |
2022-09-01 | PHASE1; PHASE2 |
| NCT05718882 | TERMINATED | Liver Cancer; Hepatocellular Carcinoma; Resistant Cancer |
RenJi Hospital |
2023-08-30 | |
| NCT04368078 | UNKNOWN | Hepatocellular Carcinoma |
Peking Union Medical College Hospital |
2020-07-11 | PHASE2 |
| NCT02720068 | COMPLETED | Neoplasms |
Merck Sharp & Dohme LLC |
2016-05-02 | PHASE1 |
| NCT05010668 | COMPLETED | Intrahepatic Cholangiocarcinoma |
Fudan University |
2021-08-24 | PHASE2 |
| NCT02592356 | COMPLETED | Differentiated Thyroid Gland Carcinoma; Malignant Adrenal Gland Pheochromocytoma; Malignant Paraganglioma; Thyroid Gland Medullary Carcinoma |
M.D. Anderson Cancer Center |
2015-11-16 | |
| NCT05312216 | UNKNOWN | Hepatocellular Carcinoma |
Zhejiang University |
2023-04 | PHASE2 |
| NCT05220020 | UNKNOWN | Hepatocellular Carcinoma |
Sun Yat-sen University |
2022-05-18 | PHASE3 |
| NCT05846724 | Not yet recruiting | Kaposi Sarcoma|Classic Kaposi Sarcoma|Refractory Kaposi Sarcoma |
Fondazione IRCCS Ca'' Granda Ospedale Maggiore Policlinico |
2024-02-01 | Phase 2 |
| NCT04193553 | COMPLETED | Gastro Intestinal Stromal Tumour |
Centre Leon Berard |
2020-01-17 | PHASE2 |
| NCT04729348 | TERMINATED | Solid Tumor; Solid Tumor, Adult; Leptomeningeal Metastasis |
Massachusetts General Hospital |
2021-03-08 | PHASE2 |
| NCT05582278 | UNKNOWN | Unresectable Hepatocellular Carcinoma |
Wen Li |
2021-01-01 | PHASE2 |
| NCT05903833 | Not yet recruiting | Recurrent Vulvar Cancer|Persistent Vulvar Cancer|Metastatic Vulva Cancer|Locally Advanced Vulvar Cancer |
AGO Research GmbH |
2024-01-01 | Phase 2 |
| NCT04699071 | UNKNOWN | Adenocarcinomas; Recurrent Gynecological |
National University Hospital, Singapore |
2021-02-18 | PHASE2 |
| NCT05485883 | UNKNOWN | Advanced Kidney Cancer |
Tianjin Medical University Second Hospital |
2022-07-01 | PHASE2 |
| NCT05254847 | COMPLETED | Biliary Tract Cancer |
Fudan University |
2022-02-24 | PHASE2 |
| NCT05485896 | COMPLETED | Renal Cell Carcinoma |
Tianjin Medical University Second Hospital |
2022-07-01 | PHASE2 |
| NCT05250843 | UNKNOWN | Hepatocellular Carcinoma |
Third Affiliated Hospital, Sun Yat-Sen University |
2022-05-30 | PHASE2; PHASE3 |
| NCT05935579 | UNKNOWN | Biliary Tract Neoplasms; Immunotherapy |
Peking Union Medical College Hospital |
2022-12-14 | PHASE2 |
| NCT05166239 | COMPLETED | Hepatocellular Carcinoma; Portal Vein Thrombosis |
Peking University |
2022-01-10 | PHASE2 |
| NCT04731740 | WITHDRAWN | Metastatic Thyroid Gland Carcinoma; Poorly Differentiated Thyroid Gland Carcinoma; Thyroid Gland Anaplastic Carcinoma by AJCC V8 Stage |
Saint Petersburg State University, Russia |
2020-12-28 | PHASE2 |
| NCT03477175 | COMPLETED | Solid Tumors |
Eisai Inc. |
2018-08-16 | PHASE2 |
| NCT05290220 | UNKNOWN | Advanced Hepatocellular Carcinoma |
Shanghai Henlius Biotech |
2022-08-01 | PHASE2 |
| NCT05131698 | UNKNOWN | Tislelizumab; Lenvatinib; TACE; Advanced Unresectable Hepatocellular Carcinoma |
Cancer Hospital of Guangxi Medical University |
2021-03-01 | EARLY_PHASE1 |
| NCT05162898 | UNKNOWN | Recurrent Hepatocellular Cancer |
Henan Cancer Hospital |
2022-01 | |
| NCT04875585 | RECRUITING | Non Small Cell Lung Cancer |
Medical University Innsbruck |
2021-05-12 | PHASE2 |
| NCT04444167 | COMPLETED | Hepatocellular Carcinoma |
Akeso |
2020-07-07 | PHASE1; PHASE2 |
| NCT05056337 | UNKNOWN | Hepatocellular Carcinoma |
Shanghai Zhongshan Hospital |
2021-08-01 | PHASE3 |
| NCT04519151 | RECRUITING | Ovarian Neoplasms; Carcinoma, Ovarian Epithelial; Neoplasm of Stomach; Ovarian Diseases; Genital Neoplasms, Female; Ovarian Epithelial Tumor; Urogenital Neoplasms; Neoplasms, Glandular and Epithelial |
Sheba Medical Center |
2021-04-12 | PHASE2 |
| NCT05582109 | UNKNOWN | Objective Response Rate (ORR) |
Tianjin Medical University Cancer Institute and Hospital |
2022-10-30 | PHASE2 |
| NCT05014828 | COMPLETED | Advanced Solid Tumor |
BeiGene |
2021-09-18 | PHASE2 |
| NCT03776136 | COMPLETED | Advanced Melanoma |
Merck Sharp & Dohme LLC |
2019-01-30 | PHASE2 |
| NCT03884101 | COMPLETED | Endometrial Neoplasms |
Merck Sharp & Dohme LLC |
2019-04-11 | PHASE3 |
| NCT04865289 | COMPLETED | Endometrial Neoplasms |
Merck Sharp & Dohme LLC |
2019-10-22 | PHASE3 |
| NCT05322187 | UNKNOWN | Transitional Cell Tumor; Hepatoblastoma; Liver Cancer; Pediatric Solid Tumor; Pediatric Cancer |
RenJi Hospital |
2022-04-10 | PHASE2; PHASE3 |
| NCT04203901 | TERMINATED | Advanced Renal Cell Carcinoma |
CoImmune |
2020-07-22 | PHASE2 |
| NCT03324373 | COMPLETED | Renal Cell Carcinoma |
Yousef Zakharia |
2019-03-20 | PHASE1 |
| NCT04361331 | COMPLETED | Cholangiocarcinoma, Intrahepatic |
Shanghai Zhongshan Hospital |
2020-03-06 | PHASE2 |
| NCT05523323 | COMPLETED | Head and Neck Squamous Cell Carcinoma |
Merck Sharp & Dohme LLC |
2020-10-30 | PHASE3 |
| NCT05319431 | ACTIVE_NOT_RECRUITING | Unresectable, Non-metastatic Hepatocellular Carcinoma |
Akeso |
2022-06-28 | PHASE2 |
| NCT03976375 | COMPLETED | Metastatic Non-Small Cell Lung Cancer |
Merck Sharp & Dohme LLC |
2019-06-26 | PHASE3 |
| NCT03829319 | COMPLETED | Nonsquamous Non-small Cell Lung Cancer |
Merck Sharp & Dohme LLC |
2019-03-25 | PHASE3 |
| NCT03867370 | TERMINATED | Hepatocellular Carcinoma |
Shanghai Junshi Bioscience Co., Ltd. |
2019-04-26 | PHASE1; PHASE2 |
| NCT04297254 | COMPLETED | Carcinoma, Hepatocellular |
Eisai Pharmaceuticals India Pvt. Ltd |
2021-02-04 | PHASE4 |
| NCT05411757 | UNKNOWN | Advanced Primary Liver Cancer |
Shandong Public Health Clinical Center |
2022-06-30 | EARLY_PHASE1 |
| NCT05620498 | UNKNOWN | Potentially Resectable Locally Advanced Intrahepatic Cholangiocarcinoma and Gallbladder Cancer |
Tianjin Medical University Cancer Institute and Hospital |
2022-09-08 | PHASE2 |
| NCT05042336 | UNKNOWN | Carrelizumab Plus Lenvatinib Combined With TACE; Borderline Resectable Hepatocellular Carcinoma |
Sichuan University |
2021-09-01 | PHASE1; PHASE2 |
| NCT05901194 | Not yet recruiting | Hepatocellular Carcinoma Non-resectable |
Assistance Publique - Hôpitaux de Paris|Laboratoire EISAI |
2023-06 | Phase 1|Phase 2 |
| NCT04199104 | COMPLETED | Head and Neck Squamous Cell Carcinoma |
Merck Sharp & Dohme LLC |
2020-02-05 | PHASE3 |
| NCT05003700 | COMPLETED | Hepatocellular Carcinoma |
Nanfang Hospital, Southern Medical University |
2021-08-12 | PHASE2 |
| NCT04531228 | UNKNOWN | Hepatocellular Carcinoma; Transarterial Chemoembolization |
Yunfei Yuan |
2020-10-11 | |
| NCT03905967 | UNKNOWN | Advanced Hepatocellular Carcinoma |
Sun Yat-sen University |
2019-06-16 | PHASE3 |
| NCT04642547 | COMPLETED | Hepatocellular Carcinoma; Molecular Targeted Therapy |
RenJi Hospital |
2020-12-02 | |
| NCT05221775 | UNKNOWN | First-line Treatment; Advanced Gastric Carcinoma |
Tianjin Medical University Cancer Institute and Hospital |
2021-11-01 | PHASE1 |
| NCT05592197 | WITHDRAWN | Advanced Hepatocellular Carcinoma |
Sun Yat-sen University |
2018-10-01 | |
| NCT05509478 | UNKNOWN | Biliary Tract Cancer |
The First Hospital of Jilin University |
2022-08-20 | PHASE2 |
| NCT04207086 | ACTIVE_NOT_RECRUITING | Melanoma Stage III |
Melanoma Institute Australia |
2020-11-11 | PHASE2 |
| NCT04889118 | COMPLETED | Malignant Melanoma |
Merck Sharp & Dohme LLC |
2020-07-14 | PHASE3 |
| NCT03820986 | COMPLETED | Malignant Melanoma |
Merck Sharp & Dohme LLC |
2019-03-12 | PHASE3 |
| NCT03290079 | COMPLETED | Neuroendocrine Tumors; Neuroendocrine Carcinoma; Neuroendocrine Cancer |
H. Lee Moffitt Cancer Center and Research Institute |
2017-12-15 | PHASE2 |
| NCT05555316 | UNKNOWN | Liver Tumor |
Sun Yat-sen University |
2019-11-10 | PHASE2 |
| NCT05171530 | UNKNOWN | HER2-negative Advanced Gastric Cancer |
Ruijin Hospital |
2022-01-05 | PHASE1 |
| NCT04053972 | UNKNOWN | Hepatocellular Carcinoma |
Sun Yat-sen University |
2018-01-31 | PHASE3 |
| NCT04053985 | UNKNOWN | Hepatocellular Carcinoma |
Sun Yat-sen University |
2018-01-01 | PHASE3 |
| NCT05391867 | UNKNOWN | Hepatocellular Carcinoma |
Sir Salimullah Medical College Mitford Hospital |
2022-01-01 | |
| NCT04974281 | UNKNOWN | Hepatocellular Carcinoma |
Fudan University |
2021-01-01 | EARLY_PHASE1 |
| NCT04814043 | UNKNOWN | Hepatocellular Carcinoma |
Sun Yat-sen University |
2021-04-20 | PHASE2 |
| NCT04229355 | UNKNOWN | Hepatocellular Carcinoma |
Guangxi Medical University |
2021-02-02 | PHASE3 |
| NCT05422183 | UNKNOWN | Ovarian Cancer, Epithelial |
Zhongda Hospital |
2022-06-30 | PHASE2 |
| NCT03418922 | COMPLETED | Carcinoma, Hepatocellular |
Eisai Co., Ltd. |
2018-01-16 | PHASE1 |
| NCT03732495 | UNKNOWN | Thyroid Cancer Metastatic |
Centre Leon Berard |
2019-07-26 | PHASE2 |
| NCT04929392 | ACTIVE_NOT_RECRUITING | Clinical Stage I Gastroesophageal Junction Adenocarcinoma AJCC v8; Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8; Clinical Stage IIA Gastroesophageal Junction Adenocarcinoma AJCC v8; Clinical Stage IIB Gastroesophageal Junction Adenocarcinoma AJCC v8; Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8; Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8; Esophageal Adenocarcinoma; Esophageal Squamous Cell Carcinoma; Pathologic Stage I Gastroesophageal Junction Adenocarcinoma AJCC v8; Pathologic Stage IA Gastroesophageal Junction Adenocarcinoma AJCC v8; Pathologic Stage IB Gastroesophageal Junction Adenocarcinoma AJCC v8; Pathologic Stage IC Gastroesophageal Junction Adenocarcinoma AJCC v8; Pathologic Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8; Pathologic Stage IIA Gastroesophageal Junction Adenocarcinoma AJCC v8; Pathologic Stage IIB Gastroesophageal Junction Adenocarcinoma AJCC v8; Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8; Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8; Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8; Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8 |
City of Hope Medical Center |
2022-01-25 | PHASE2 |
| NCT04401800 | COMPLETED | Hepatocellular Carcinoma; Unresectable Hepatocellular Carcinoma; Metastatic Hepatocellular Carcinoma |
BeiGene |
2020-09-04 | PHASE2 |
| NCT04687163 | UNKNOWN | Hepatocellular Carcinoma |
Sun Yat-sen University |
2020-12-30 | PHASE3 |
| NCT05277675 | UNKNOWN | Hepatocellular Carcinoma Recurrent |
Southwest Hospital, China |
2021-11-01 | |
| NCT03841201 | COMPLETED | Advanced Hepatocellular Carcinoma |
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest |
2019-06-12 | PHASE2 |
| NCT03524326 | COMPLETED | Head and Neck Squamous Cell Carcinoma; Cutaneous Squamous Cell Carcinoma; Head and Neck Cancer; Head and Neck Carcinoma |
Memorial Sloan Kettering Cancer Center |
2018-04-30 | PHASE1 |
| NCT03245151 | COMPLETED | Recurrent and Refractory Solid Tumors |
Eisai Inc. |
2017-11-16 | PHASE1; PHASE2 |
| NCT04447755 | COMPLETED | Relapsed or Refractory Solid Tumors |
Merck Sharp & Dohme LLC |
2020-07-30 | PHASE2 |
| NCT04909866 | UNKNOWN | Hepatocellular Carcinoma |
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology |
2021-01-01 | PHASE2; PHASE3 |
| NCT05213221 | COMPLETED | Advanced Hepatocellular Carcinoma |
Zhejiang University |
2022-03-14 | PHASE2 |
| NCT04168944 | UNKNOWN | Hepatocellular Carcinoma |
RenJi Hospital |
2019-11 | PHASE2; PHASE3 |
| NCT04042805 | UNKNOWN | Hepatocellular Carcinoma |
Baocai Xing |
2019-08-01 | PHASE2 |
| NCT02973997 | COMPLETED | Columnar Cell Variant Thyroid Gland Papillary Carcinoma; Follicular Variant Thyroid Gland Papillary Carcinoma; Metastatic Thyroid Gland Follicular Carcinoma; Metastatic Thyroid Gland Papillary Carcinoma; Poorly Differentiated Thyroid Gland Carcinoma; Recurrent Differentiated Thyroid Gland Carcinoma; Recurrent Thyroid Gland Follicular Carcinoma; Recurrent Thyroid Gland Papillary Carcinoma; Stage III Differentiated Thyroid Gland Carcinoma AJCC v7; Stage III Thyroid Gland Follicular Carcinoma AJCC v7; Stage III Thyroid Gland Papillary Carcinoma AJCC v7; Stage IV Thyroid Gland Follicular Carcinoma AJCC v7; Stage IV Thyroid Gland Papillary Carcinoma AJCC v7; Stage IVA Differentiated Thyroid Gland Carcinoma AJCC v7; Stage IVA Thyroid Gland Follicular Carcinoma AJCC v7; Stage IVA Thyroid Gland Papillary Carcinoma AJCC v7; Stage IVB Differentiated Thyroid Gland Carcinoma AJCC v7; Stage IVB Thyroid Gland Follicular Carcinoma AJCC v7; Stage IVB Thyroid Gland Papillary Carcinoma AJCC v7; Stage IVC Differentiated Thyroid Gland Carcinoma AJCC v7; Stage IVC Thyroid Gland Follicular Carcinoma AJCC v7; Stage IVC Thyroid Gland Papillary Carcinoma AJCC v7; Tall Cell Variant Thyroid Gland Papillary Carcinoma; Thyroid Gland Hurthle Cell Carcinoma; Unresectable Differentiated Thyroid Gland Carcinoma; Unresectable Thyroid Gland Carcinoma |
Academic and Community Cancer Research United |
2018-02-07 | PHASE2 |
| NCT04728321 | COMPLETED | Hepatocellular Carcinoma |
Akeso |
2021-01-27 | PHASE2 |
| NCT04490694 | UNKNOWN | Hepatocellular Carcinoma |
Shanghai Zhongshan Hospital |
2020-03-01 | PHASE2 |
| NCT04961918 | UNKNOWN | Hepatocellular Carcinoma |
Sun Yat-sen University |
2021-07-13 | PHASE2 |
| NCT05036798 | UNKNOWN | Potentially Resectable Locally Advanced Malignant Tumors of Biliary System |
Tianjin Medical University Cancer Institute and Hospital |
2021-09-17 | PHASE2 |
| NCT05007587 | UNKNOWN | Hepatocellular Carcinoma Stage IIIa |
Zhejiang Cancer Hospital |
2021-07-01 | EARLY_PHASE1 |
| NCT03838796 | UNKNOWN | Hepatocellular Carcinoma |
Fudan University |
2019-01-03 | |
| NCT03713593 | COMPLETED | Carcinoma, Hepatocellular |
Merck Sharp & Dohme LLC |
2018-12-31 | PHASE3 |
| NCT04443049 | UNKNOWN | Hepatocellular Carcinoma; Liver Cirrhosis |
Institute of Liver and Biliary Sciences, India |
2020-07-10 | |
| NCT03139747 | SUSPENDED | Thyroid Cancer |
Thomas Jefferson University |
2017-04-03 | PHASE2 |
| NCT04834986 | UNKNOWN | Resectable Hepatocellular Carcinoma |
Tianjin Medical University Cancer Institute and Hospital |
2021-04-30 | PHASE2 |
| NCT03517449 | COMPLETED | Endometrial Neoplasms |
Eisai Inc. |
2018-06-11 | PHASE3 |
| NCT03791918 | WITHDRAWN | Hepatocellular Carcinoma |
Sun Yat-sen University |
2019-01-01 | PHASE3 |
| NCT04237740 | UNKNOWN | Hepatocellular Carcinoma; Liver Transplantation |
RenJi Hospital |
2020-05-01 | PHASE3 |
| NCT02788708 | COMPLETED | Fallopian Tube Carcinoma; Recurrent Ovarian Cancer; Primary Peritoneal Carcinoma; Recurrent Endometrial Cancer |
Floor Backes |
2016-05-27 | PHASE1 |
| NCT04443322 | UNKNOWN | Liver Carcinoma; Liver Transplant; Complications |
RenJi Hospital |
2020-09-19 | |
| NCT04227808 | UNKNOWN | Hepatocellular Carcinoma (HCC) |
Shanghai Zhongshan Hospital |
2019-12-12 | PHASE2 |
| NCT04618367 | COMPLETED | Carcinoma, Hepatocellular; Liver Neoplasms; Sintilimab; Portal Vein Tumor Thrombus |
Sun Yat-sen University |
2021-01-01 | |
| NCT04622566 | NOT_YET_RECRUITING | Mucosal Melanoma; Neoadjuvant Treatment |
Peking University Cancer Hospital & Institute |
2020-12-30 | PHASE2 |
| NCT03775395 | UNKNOWN | Hepatocellular Carcinoma |
Sun Yat-sen University |
2018-12-12 | PHASE3 |
| NCT04769908 | UNKNOWN | ICC |
Sun Yat-sen University |
2021-02-23 | PHASE2 |
| NCT04599790 | COMPLETED | Hepatocellular Carcinoma Non-resectable |
Second Affiliated Hospital of Guangzhou Medical University |
2020-10-01 | PHASE2 |
| NCT04241523 | UNKNOWN | Hepatocellular Carcinoma (HCC) |
Shanghai Zhongshan Hospital |
2020-01 | PHASE2 |
| NCT04506281 | UNKNOWN | Cholangiocarcinoma, Intrahepatic |
Shanghai Zhongshan Hospital |
2020-08-10 | PHASE2 |
| NCT03898180 | COMPLETED | Urothelial Carcinoma |
Merck Sharp & Dohme LLC |
2019-05-06 | PHASE3 |
| NCT03526679 | COMPLETED | Leiomyosarcoma; Liposarcoma; Soft Tissue Sarcoma Adult; Advanced Cancer |
National Taiwan University Hospital |
2018-07-12 | PHASE1; PHASE2 |
| NCT03506048 | TERMINATED | Differentiated Thyroid Gland Carcinoma; Thyroid Gland Follicular Carcinoma; Thyroid Gland Papillary Carcinoma |
Emory University |
2019-01-16 | PHASE2 |
| NCT04527679 | UNKNOWN | Cholangiocarcinoma, Intrahepatic |
Shanghai Zhongshan Hospital |
2020-10 | PHASE2 |
| NCT04444193 | UNKNOWN | Endometrial Cancer |
Shanghai First Maternity and Infant Hospital |
2020-08-31 | |
| NCT03829332 | COMPLETED | Non-small Cell Lung Cancer |
Merck Sharp & Dohme LLC |
2019-03-13 | PHASE3 |
| NCT04676412 | COMPLETED | Non-small Cell Lung Cancer |
Merck Sharp & Dohme LLC |
2019-10-23 | PHASE3 |
| NCT03609359 | COMPLETED | Advanced Gastric Cancer |
National Cancer Center Hospital East |
2018-10-03 | PHASE2 |
| NCT04170179 | UNKNOWN | Hepatocellular Carcinoma |
Sun Yat-sen University |
2019-11-19 | PHASE2 |
| NCT03895970 | COMPLETED | Liver Neoplasm Malignant Primary; Cholangiocarcinoma; Combinational Immunotherapy; Biomarker |
Peking Union Medical College Hospital |
2019-04-20 | PHASE2 |
| NCT04044651 | WITHDRAWN | Hepatocellular Carcinoma |
Shi Ming |
2019-10-30 | PHASE2; PHASE3 |
| NCT03168074 | UNKNOWN | Breast Cancer |
National University Hospital, Singapore |
2017-03-28 | PHASE2 |
| NCT04044313 | COMPLETED | Hepatocellular Carcinoma |
Shi Ming |
2019-08-01 | PHASE2 |
| NCT04080154 | UNKNOWN | Hepatocellular Carcinoma |
Shanghai Zhongshan Hospital |
2019-09-24 | PHASE2 |
| NCT03803254 | WITHDRAWN | Hepatocellular Carcinoma |
Sun Yat-sen University |
2019-01-03 | PHASE2 |
| NCT04273100 | UNKNOWN | Hepatocellular Carcinoma Non-resectable |
Tianjin Medical University Cancer Institute and Hospital |
2019-11-14 | PHASE2 |
| NCT03878524 | TERMINATED | Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Anatomic Stage IV Breast Cancer AJCC v8; Anemia; Ann Arbor Stage III Hodgkin Lymphoma; Ann Arbor Stage III Non-Hodgkin Lymphoma; Ann Arbor Stage IV Hodgkin Lymphoma; Ann Arbor Stage IV Non-Hodgkin Lymphoma; Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative; Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Castration-Resistant Prostate Carcinoma; Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Hematopoietic and Lymphoid System Neoplasm; Locally Advanced Pancreatic Adenocarcinoma; Metastatic Breast Carcinoma; Metastatic Malignant Solid Neoplasm; Metastatic Pancreatic Adenocarcinoma; Myelodysplastic/Myeloproliferative Neoplasm With Ring Sideroblasts and Thrombocytosis; Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable; Primary Myelofibrosis; Recurrent Acute Lymphoblastic Leukemia; Recurrent Acute Myeloid Leukemia; Recurrent Chronic Lymphocytic Leukemia; Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Recurrent Hematologic Malignancy; Recurrent Hodgkin Lymphoma; Recurrent Myelodysplastic Syndrome; Recurrent Myelodysplastic/Myeloproliferative Neoplasm; Recurrent Myeloproliferative Neoplasm; Recurrent Non-Hodgkin Lymphoma; Recurrent Plasma Cell Myeloma; Recurrent Small Lymphocytic Lymphoma; Refractory Acute Lymphoblastic Leukemia; Refractory Acute Myeloid Leukemia; Refractory Chronic Lymphocytic Leukemia; Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Refractory Chronic Myelomonocytic Leukemia; Refractory Hematologic Malignancy; Refractory Hodgkin Lymphoma; Refractory Malignant Solid Neoplasm; Refractory Myelodysplastic Syndrome; Refractory Myelodysplastic/Myeloproliferative Neoplasm; Refractory Non-Hodgkin Lymphoma; Refractory Plasma Cell Myeloma; Refractory Primary Myelofibrosis; Refractory Small Lymphocytic Lymphoma; Stage II Pancreatic Cancer AJCC v8; Stage III Pancreatic Cancer AJCC v8; Stage IV Pancreatic Cancer AJCC v8; Stage IV Prostate Cancer AJCC v8; Unresectable Pancreatic Adenocarcinoma |
OHSU Knight Cancer Institute |
2020-04-01 | PHASE1 |
| NCT02640508 | COMPLETED | Cancer; Solid Tumor |
Virginia G. Kaklamani |
2016-05 | PHASE2 |
| NCT02501096 | COMPLETED | Tumors |
Eisai Inc. |
2015-07-22 | PHASE1; PHASE2 |
| NCT03005015 | WITHDRAWN | Endometrial Neoplasms |
European Organisation for Research and Treatment of Cancer - EORTC |
2017-01 | PHASE2 |
| NCT02846766 | WITHDRAWN | Cancer |
Teresa Helsten, MD |
2018-07-01 | PHASE2 |
| NCT03006887 | COMPLETED | Solid Tumors |
Eisai Co., Ltd. |
2017-01-12 | PHASE1 |
| NCT02726503 | COMPLETED | Anaplastic Thyroid Cancer |
Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan |
2016-04-04 | PHASE2 |
| NCT03173560 | COMPLETED | Renal Cell Carcinoma |
Eisai Inc. |
2017-08-17 | PHASE2 |
| NCT03779100 | SUSPENDED | Intrahepatic Cholangiocarcinoma |
Shi Ming |
2018-12-17 | PHASE2 |
| NCT03775707 | WITHDRAWN | Hepatocellular Carcinoma |
Shi Ming |
2018-12-01 | PHASE2 |
| NCT03919383 | WITHDRAWN | Hepatocellular Carcinoma |
Sun Yat-sen University |
2019-04-15 | PHASE2 |
| NCT03801499 | WITHDRAWN | Intrahepatic Cholangiocarcinoma |
Sun Yat-sen University |
2018-09-01 | PHASE2 |
| NCT03630120 | TERMINATED | Thyroid Cancer; Thyroid Cancer, Medullary; Differentiated Thyroid Cancer; Papillary Thyroid Cancer; Follicular Thyroid Cancer; Poorly Differentiated Thyroid Gland Carcinoma |
H. Lee Moffitt Cancer Center and Research Institute |
2018-08-06 | PHASE2 |
| NCT03006926 | COMPLETED | Hepatocellular Carcinoma |
Eisai Co., Ltd. |
2017-02-13 | PHASE1 |
| NCT02935309 | COMPLETED | Rectal Cancer; Rectal Adenocarcinoma |
H. Lee Moffitt Cancer Center and Research Institute |
2016-10-14 | PHASE1 |
| NCT03746249 | WITHDRAWN | Hepatocellular Carcinoma |
Sun Yat-sen University |
2018-12-17 | PHASE2 |
| NCT02966093 | COMPLETED | Differentiated Thyroid Cancer (DTC) |
Eisai Co., Ltd. |
2017-01-11 | PHASE3 |
| NCT02432274 | COMPLETED | Tumors; Solid Malignant Tumors; Osteosarcoma; Differentiated Thyroid Cancer (DTC) |
Eisai Limited |
2014-12-29 | PHASE1; PHASE2 |
| NCT02860936 | COMPLETED | Adenoid Cystic Carcinomas of the Salivary Glands |
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano |
2015-06 | PHASE2 |
| NCT03499626 | UNKNOWN | Advanced/ Metastatic Hepatocellular Carcinoma |
National University Hospital, Singapore |
2017-05-05 | PHASE1; PHASE2 |
| NCT03433703 | TERMINATED | Carcinoma, Hepatocellular |
Eisai Inc. |
2018-04-26 | PHASE2 |
| NCT03009292 | COMPLETED | Solid Tumor |
Eisai Co., Ltd. |
2018-08-06 | PHASE1 |
| NCT02657369 | TERMINATED | Thyroid Carcinoma, Anaplastic |
Eisai Inc. |
2016-07-07 | PHASE2 |
| NCT02998775 | COMPLETED | Hepatic Impairment; Renal Impairment |
Eisai Inc. |
2016-12-02 | EARLY_PHASE1 |
| NCT02953743 | COMPLETED | Unresectable Hepatocellular Carcinoma (HCC) |
Eisai Co., Ltd. |
2016-09-01 | PHASE1 |
| NCT02454478 | COMPLETED | Carcinoma, Renal Cell |
Eisai Co., Ltd. |
2015-07-01 | PHASE1 |
| NCT02686164 | COMPLETED | Tumors |
Eisai Inc. |
2016-04-18 | PHASE1 |
| NCT01761266 | COMPLETED | Hepatocellular Carcinoma (HCC) |
Eisai Limited |
2013-03-01 | PHASE3 |
| NCT01877083 | COMPLETED | KIF5B-RET-Positive Adenocarcinoma of the Lung |
Eisai Inc. |
2013-04-05 | PHASE2 |
| NCT02792829 | COMPLETED | Healthy Volunteers |
Eisai Inc. |
2014-08 | PHASE1 |
| NCT00946153 | COMPLETED | Hepatocellular Carcinoma |
Eisai Co., Ltd. |
2009-07-24 | PHASE1; PHASE2 |
| NCT01136733 | COMPLETED | Metastatic Renal Cell Carcinoma |
Eisai Inc. |
2010-08-05 | PHASE1; PHASE2 |
| NCT01133977 | COMPLETED | Stage IV Melanoma |
Eisai Inc. |
2010-04 | PHASE1; PHASE2 |
| NCT01529112 | COMPLETED | Non-Small Cell Lung Cancer |
Eisai Inc. |
2011-11 | PHASE2 |
| NCT01321554 | COMPLETED | Thyroid Cancer |
Eisai Inc. |
2011-03-17 | PHASE3 |
| NCT01136967 | COMPLETED | Unresectable Stage III; Stage IV Melanoma |
Eisai Inc. |
2010-08 | PHASE2 |
| NCT01137604 | COMPLETED | Glioma |
Eisai Inc. |
2010-11-09 | PHASE2 |
| NCT02421042 | COMPLETED | Hepatic Impairment; Hepatic Function |
Eisai Inc. |
2011-06 | PHASE1 |
| NCT01111461 | COMPLETED | Endometrial Cancer |
Eisai Inc. |
2010-03 | PHASE2 |
| NCT01133756 | TERMINATED | Ovarian Cancer |
Eisai Inc. |
2010-03 | PHASE1; PHASE2 |
| NCT02199392 | COMPLETED | P-glycoprotein; Healthy Volunteers |
Eisai Inc. |
2011-11 | PHASE1 |
| NCT01525394 | COMPLETED | Refractory Solid Tumors; Lymphomas |
Eisai Inc. |
2010-12 | PHASE1 |
| NCT00784303 | COMPLETED | Thyroid Cancer |
Eisai Inc. |
2008-11-06 | PHASE2 |
| NCT02578316 | COMPLETED | Advanced Solid Tumors; Lymphomas |
Eisai Inc. |
2009-06 | PHASE1 |
(data from https://clinicaltrials.gov, updated on 2026-09-03)
Check the
E7080 (Lenvatinib)
product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.
Mechanism and Biochemical Profile
Appendix RUO and cGMP Quality Standards
| Quality Dimension | RUO (Research Use Only) | cGMP (Current Good Manufacturing Practice) |
|---|---|---|
| Clinical Applicability | Prohibited in human clinical trials or medical diagnostics. | Mandatory for human clinical trials (Phase I–III) and therapies. |
| Regulatory Status | Non-regulated grade; exempt from drug manufacturing laws. | Legally enforced by health authorities (e.g., FDA, EMA, NMPA). |
| Facility Environment | Unclassified analytical or research laboratories. | Validated Cleanrooms (ISO Class 5–8) with continuous monitoring. |
| Quality Control | Basic purity and activity testing. | Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma). |
| Process Validation | Basic equipment calibration; no process validation required. | Full qualification (IQ/OQ/PQ) and complete batch records. |
| Quality Assurance | Vendor self-declared without required formal QMS. | Mandatory QA/QC unit, Change Control, CAPA, and vendor audits. |
| Regulatory Impact | High risk of IND rejection if used as a critical raw material. | Required for IND/NDA filings, supported by Drug Master Files (DMF). |
Footnotes
Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).
- E7080 (Lenvatinib) Mechanism of Action: VEGFR Inhibition in Endothelial Cells Research
- E7080 (Lenvatinib): Selectivity & Specificity
- E7080 (Lenvatinib) Working Concentration | Cell Culture | Treatment
- E7080 (Lenvatinib) Solubility in DMSO
- E7080 (Lenvatinib) Stock Solution
- E7080 (Lenvatinib) Storage
- E7080 (Lenvatinib) Stability
- E7080 (Lenvatinib) Combination Database
- E7080 (Lenvatinib) Molecular Weight
- E7080 (Lenvatinib) SMILES
- E7080 (Lenvatinib) CAS Number
- E7080 (Lenvatinib) Chemical Structure (2D and 3D)
- E7080 (Lenvatinib) IC50 for Cell-based and Cell-free Assays
- E7080 (Lenvatinib) Sigma (SML3017)? Try a better option.
- E7080 (Lenvatinib) MedChemExpress (HY-10981)? Try a better option.
- E7080 (Lenvatinib) Cayman (19375)? Try a better option.
- E7080 (Lenvatinib) Abmole (M1841)? Try a better option.
- E7080 (Lenvatinib) SDS｜MSDS
Note: Technical data last updated: Sep 1, 2026.